Legal Representation
Attorney
Cynthia J. Walden
USPTO Deadlines 2 active 2 overdue
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
EXAMINER AMENDMENT
Examiner's Amendment Completed |
CNEA | Jan 06, 2023 | 913 days overdue | Low | No |
|
OPPOSITION
Notice of Publication |
NPUB | Feb 23, 2023 | 865 days overdue | Medium | Until Mar 23, 2023 |
Application History
19 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 11, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Apr 11, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jan 24, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 24, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jan 4, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 22, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Dec 22, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Dec 22, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Dec 22, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Dec 22, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 23, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jun 23, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jun 23, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 28, 2021 | ALIE | A | ASSIGNED TO LIE |
| Oct 28, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Oct 22, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 5, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Sep 21, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Development of platform technology, namely, immunotherapy pharmaceutical platforms for use in manufacturing therapeutics related to inflammaging, inflammatory diseases, age-related diseases and cancer; Medical and scientific research and development services in the field of protein therapeutics and immunotherapeutics; pharmaceutical product development; pharmaceutical research and development services; Research and development of pharmaceuticals for the treatment of age-related and inflammatory diseases and cancer
First Use Anywhere:
May 28, 2018
First Use in Commerce:
May 28, 2018
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOLOGICS"